Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudineresistant HBV in vitro

Hepatology

Volumn 37, Issue 1, 2003, Pages 27-35

  Chen, Robert Y M ^a,b   Edwards, Ros ^a   Shaw, Tim ^a   Colledge, Danni ^a   Delaney IV, William E ^a   Isom, Harriet ^c   Bowden, Scott ^a   Desmond, Paul ^b   Locarnini, Stephen A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ANIMAL CELL; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENETIC CODE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STOP CODON; VIRUS GENE; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

EID: 0037221770     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50012     Document Type: Article

References (50)

1. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624.
2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-591.
3. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-1303.
4. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991;88:4186-4190.
5. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994;91:4077-4081.
6. Lok AS. Hepatitis B infection: Pathogenesis and management. J Hepatol 2000;32:89-97.
7. Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-141.
8. Lai C, Chien R, Leung N, Chang T, Guan R, Tai D, Ng K, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
9. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
10. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
11. Delaney WE IV, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation. Antiviral Chem Chemother 2001;12:1-35.
12. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
13. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395.
14. Honkoop P, de Man RA, Niesters HG, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998;29:510-511.
15. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
16. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896.
17. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851.
18. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
19. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNApositive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
20. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, Lamy P, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999;68:1912-1914.
21. Fu L, Cheng Y-C. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother 2000;44:3402-3407.
22. Yaginuma K, Shirakata Y, Kobayashi M, Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci U S A 1987;84:2678-2682.
23. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-&-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501.
24. Delaney WE IV, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998;28:1134-1146.
25. Delaney WE IV, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45:1705-1713.
26. O'Reilly D. Use of baculovirus expression vectors. Methods Mol Biol 1997;62:235-246.
27. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadanaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-225.
28. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000;44:551-560.
29. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A 1996;93:2348-2352.
30. Marcellin P, Chang T-T, Lim S-G, Tong M, Sievert W, Shiffman M, Jeffers Lea. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results [Abstract]. Hepatology 2001;34: 340A.
31. Heathcote E, Thai Q, Margulies M, Tsiang M, Friy J, Gibbs CS, Westland CE, et al. Adefovir dipivoxil (ADV) for HBeAg negative chronic hepatitis B (HBV): Virological and comparative viral dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral clearance [Abstract]. J Hepatol 2001;34(Suppl 1):167A.
32. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000;32:1163-1169.
33. Laras A, Dimou E, Hadziyannis S. Conservation of HBV core promoter and precore sequences during the course of long-term lamivudine monotherapy [Abstract]. Hepatology 2001;34:324A.
34. Melegari M, Scaglioni P, Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
35. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998;55:1567-1572.
36. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-945.
37. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, et al. The polymerase L528M mutation cooperates with nucleotide bindingsite mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455.
38. Nassal M, Schaller H. Hepatitis B virus replication - An update. J Viral Hepatitis 1996;3:217-226.
39. Tavis J. The replication strategy of the hepadanaviruses. Viral Hepatitis Rev 1996;2:205-218.
40. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990;9:3389-3396.
41. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992;11:3413-3420.
42. Pollack JR, Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol 1993;67:3254-3263.
43. Tong SP, Li JS, Vitvitski L, Trepo C. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: Relevance of pregenome encapsidation signal. Virology 1992;191:237-245.
44. Tong SP, Diot C, Gripon P, Li J, Vitvitski L, Trepo C, Guguen-Guillouzo C. In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology 1991;181:733-737.
45. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997;233:374-381.
46. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997;71:345-353.
47. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precoremediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993;67:3756-3762.
48. Guidotti LG, Matzke B, Pasquinelli C, Schoenberger JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996;70:7056-7061.
49. Davis MG, Wilson JE, VanDraanen NA, Miller WH, Freeman GA, Daluge SM, Boyd FL, et al. DNA polymerase activity of hepatitis B virus particles: Differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res 1996;30:133-145.
50. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-867.